Answers are grounded in this paper and cite their sources.
Paediatric Burkitt's lymphoma (pBL) is the most common childhood non-Hodgkin B-cell lymphoma. Despite the encouraging survival rates for most children, treating cases with relapse/resistance to current therapies remains challenging. CD38 is a transmembrane protein highly expressed in pBL. This study investigates the effectiveness of CD38-targeting monoclonal antibodies (mAbs), daratumumab and isatuximab, in impairing crucial cellular processes and survival pathways in pBL malignant cells.
No takes yet. Share an insight, caveat, or question.
Kläsener et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: